Restoring order at the cell cycle border: Co-targeting CDK4/6 and CDK2

被引：9

作者：

Jeselsohn, Rinath ^{[1
,2
,3
]}

Schiff, Rachel ^{[4
,5
]}

Grinshpun, Albert ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Breast Oncol Ctr, Boston, MA 02115 USA

[2] Dana Farber Canc Inst, Div Mol & Cellular Oncol, Boston, MA 02115 USA

[3] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02115 USA

[4] Baylor Coll Med, Dept Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA

[5] Baylor Coll Med, Dept Mol & Cellular Biol, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA

来源：

CANCER CELL | 2021年 / 39卷 / 10期

关键词：

D O I：

10.1016/j.ccell.2021.08.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Overcoming resistance to CDK4/6 inhibitors is a major clinical challenge. In this issue of Cancer Cell, Freeman-Cook et al. study mechanisms of resistance to CDK4/6 inhibitors by employing a CRISPRa screen. They identify the cyclin E-CDK2 axis and Myc signaling as key pathways of resistance and develop PF-06873600, a selective CDK2/4/6 inhibitor.

引用

页码：1302 / 1305

页数：5

共 50 条

[1] Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
Abeer J. Al-Qasem
Carla L. Alves
Sidse Ehmsen
Martina Tuttolomondo
Mikkel G. Terp
Lene E. Johansen
Henriette Vever
Luna V. A. Hoeg
Daniel Elias
Martin Bak
Henrik J. Ditzel
npj Precision Oncology, 6
[2] Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
Al-Qasem, Abeer J.
Alves, Carla L.
Ehmsen, Sidse
Tuttolomondo, Martina
Terp, Mikkel G.
Johansen, Lene E.
Vever, Henriette
Hoeg, Luna V. A.
Elias, Daniel
Bak, Martin
Ditzel, Henrik J.
NPJ PRECISION ONCOLOGY, 2022, 6 (01)
[3] Slower CDK4 and faster CDK2 activation in the cell cycle
Zhang, Wengang
Liu, Yonglan
Jang, Hyunbum
Nussinov, Ruth
STRUCTURE, 2024, 32 (08)
[4] Targeting the cell cycle - Beyond CDK4/6 inhibition
Jeselsohn, R.
CANCER RESEARCH, 2020, 80 (04)
[5] CHROMOSOMAL MAPPING OF HUMAN CDK2, CDK4, AND CDK5 CELL-CYCLE KINASE GENES
DEMETRICK, DJ
ZHANG, H
BEACH, DH
CYTOGENETICS AND CELL GENETICS, 1994, 66 (01): : 72 - 74
[6] Mice thrive without Cdk4 and Cdk2
Barriere, Cedric
Santamaria, David
Cerqueira, Antonio
Galan, Javier
Martin, Alberto
Ortega, Sagrario
Malumbres, Marcos
Dubus, Pierre
Barbacid, Mariano
MOLECULAR ONCOLOGY, 2007, 1 (01): : 72 - 83
[7] Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
Piezzo, Michela
Cocco, Stefania
Caputo, Roberta
Cianniello, Daniela
Di Gioia, Germira
Di Lauro, Vincenzo
Fusco, Giuseppina
Martinelli, Claudia
Nuzzo, Francesco
Pensabene, Matilde
De Laurentiis, Michelino
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (18) : 1 - 23
[8] CDK2 and CDK4/6 inhibition in GIST: Mechanisms of response and resistance
Schaefer, Inga-Marie
Hemming, Matthew L.
Lundberg, Meijun Z.
Serrata, Matthew P.
Goldaracena, Isabel
Liu, Ninning
Yin, Peng
Paulo, Joao A.
Gygi, Steven P.
George, Suzanne
Morgan, Jeffrey A.
Bertagnolli, Monica M.
Sicinska, Ewa T.
Marino-Enriquez, Adrian
Hornick, Jason L.
Raut, Chandrajit P.
Demetri, George D.
Ou, Wen-Bin
Saka, Sinem K.
Fletcher, Jonathan A.
CLINICAL CANCER RESEARCH, 2022, 28 (18)
[9] Response and resistance to CDK2 and CDK4/6 inhibition in GIST.
Schaefer, Inga-Marie
Lundberg, Meijun Z.
Hemming, Matthew L.
Saka, Sinem K.
Serrata, Matthew P.
Goldaracena, Isabel
Liu, Ninning
Yin, Peng
Paulo, Joao A.
Gygi, Steven
Demetri, George D.
Sicinska, Ewa
Marino-Enriquez, Adrian
Hornick, Jason L.
Raut, Chandrajit P.
Ou, Wen-Bin
Fletcher, Jonathan A.
CANCER RESEARCH, 2022, 82 (12)
[10] Targeting CDK4 and CDK6 in cancer
Shom Goel
Johann S. Bergholz
Jean J. Zhao
Nature Reviews Cancer, 2022, 22 : 356 - 372

← 1 2 3 4 5 →